Evotec and Vifor Pharma form joint venture
Evotec SE and Vifor Pharma announced the launch of a 50:50 joint venture focused on the discovery and development of novel nephrology therapeutics. Vifor Pharma will be benefiting from access to an external R&D capability for the development of its own nephrology pipeline, while Evotec will gain access to a commercial partner through outlicensing all nephrology assets developed through the joint venture to the Vifor Pharma Group.
Under the terms of the agreement, the joint venture will focus on the discovery of nephrology therapeutics by analysing the clinical data provided by Evotec that is mining a unique UK kidney biobank, NURTuRE, in order to identify new targets for renal therapies, and sharpen existing product profiles of an innovative pipeline. Evotec will focus on applying its drug discovery & development capabilities and will leverage Vifor Pharma’s proven commercial platform to create a robust pipeline of nephrology programmes. Upon completion of clinical trials for drugs in the newly-created, jointly-owned pipeline, products will be outlicensed to Vifor Pharma for registration and commercialisation to further expand Vifor Pharma Group’s strong nephrology pipeline.
Initial funding of € 25 m for pre-clinical development will be covered by Vifor Pharma so that multiple targets or candidates can be moved forward simultaneously. The use of Evotec’s proprietary PanHunter bioinformatics platform, combined with high-quality data sets from thousands of human kidney disease patients will lead to the discovery of a number of promising therapeutic options in the kidney disease space. The clinical and commercial costs for any successful compounds are anticipated to be shared equally by both companies, with opt-out rights at each stage based on a predetermined profit share arrangement.
Dr Cord Dohrmann, Chief Scientific Officer at Evotec, commented: “We are excited to be entering into this highly complementary joint venture with Vifor Pharma. The partnership will help us maximise the potential of our early-stage target identification and candidate selection platform in nephrology by creating a joint company with one of the world leaders in nephrology clinical development and commercialisation. This will allow Evotec to participate in the value generation of clinical development.”
Stefan Schulze, COO and President of the Executive Committee at Vifor Pharma, commented: “The creation of the joint venture will enable us to identify new targets for renal therapies to bolster our pipeline. We will now have access to Evotec’s best-in-class drug discovery as well as pre-clinical capabilities without having to expand our own R&D infrastructure. By drawing on the unique strengths of Vifor Pharma and Evotec, this joint venture will create a powerful research platform and contribute to establish Vifor Pharma as a global leader in nephrology.”
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Antisoma's ASA404 enters pivotal phase III trial in second-line lung cancer
Activation against Malaria: Facile Oxidation of Leucomethylene Blue and Dihydroflavins by Artemisinins
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology
Brain cancer cells hide while drugs seek - Tumor cells temporarily lose mutation to evade drugs targeting mutation
Biosciences' Nimotuzumab Selected for Multinational Phase III Trial by National Cancer Centre of Singapore - Singapore investigators to coordinate 700 patient trial of EGFR targeting antibody for treatment of head and neck cancer
Merck to Become First Provider to Offer Fully Integrated mRNA Services - New sites at Darmstadt and Hamburg complement Merck’s global integrated mRNA service network
FDA grants Orphan Drug Status for to-BBB’s lead product
Phase 2a Study of HIV-1 Investigational Maturation Inhibitor - Demonstration of positive results for therapy designed to attack virus in a new way
Oxyrane Raises $26.5m in Series D Financing
InfectoPharm invests in AudioCure to advance innovative hearing loss therapy - Drug candidate AC102 in the clinical phase
